The Medical Letter on Drugs and Therapeutics
Liraglutide (Victoza) for Type 2 Diabetes
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Liraglutide (Victoza – Novo Nordisk), a glucagon-like peptide-1 (GLP-1) receptor agonist given by subcutaneous injection, has been approved by the FDA for treatment of patients with type 2 diabetes. It can be used alone or in addition to oral antidiabetic drugs such as metformin (Glucophage, and others) or glimepiride (Amaryl, and others). Liraglutide is not recommended for first-line therapy and is not approved for use with insulin.

GLUCAGON-LIKE PEPTIDE (GLP-1) RECEPTOR AGONISTS — Liraglutide is the second GLP-1 agonist marketed in the US; exenatide (Byetta), the first, has been available since 2005.1 A long-acting formulation of exenatide (Bydureon) given only once each week may be available soon.2

MECHANISM OF ACTION — Liraglutide is structurally similar to native human GLP-1. It lowers blood glucose ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Liraglutide (Victoza) for Type 2 Diabetes
Article code: 1335a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian